New updates have been reported about Goodpath.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Goodpath has introduced new direct-to-employer and self-pay pathways for Wegovy, including both injectable and newly approved oral versions, through a collaboration with Novo Nordisk. The offering is designed to sit outside traditional pharmacy benefit structures, giving employers transparent GLP-1 pricing and control over subsidy levels and member cost sharing while Goodpath provides physician-led clinical oversight.
By bypassing conventional PBM-controlled formularies and rebate models, Goodpath aims to give employers clearer visibility into GLP-1 utilization and spending, with its direct-to-employer program projected to lower obesity medication costs by 35% or more. The company integrates Wegovy into a broader, whole-person weight care model that addresses comorbidities such as diabetes, musculoskeletal pain, digestive issues, mental health conditions, and sleep disorders, with clinicians tailoring oral or injectable therapy based on each member’s clinical profile and long-term health goals.
Goodpath CEO Bill Gianoukos said current benefit designs are struggling to keep pace with rising GLP-1 demand and often separate medication from behavior change support and ongoing clinical management. He emphasized that Goodpath’s approach allows employers to structure Wegovy coverage to fit their population while supporting adherence, managing side effects, and targeting lower total cost of care through integrated, longitudinal care.
The collaboration also positions Goodpath to expand its reach among employers seeking more sustainable approaches to obesity and cardiometabolic risk management. Novo Nordisk executive Ed Cinca highlighted that Wegovy can play a role not only in weight management but also in addressing cardiovascular risk and MASH, and said the company views Goodpath as a partner aligned on improving long-term patient outcomes through flexible, patient-centered access models.